Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Escudier

Showing results (41-50 of 362) with videos related to

Pageof 37
Sort By:
Future Oncology (London, England)|October 18, 2014
Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trialAmikumar Mehta, Guru Sonpavde, Bernard Escudier
European Urology|March 28, 2021
Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?Laurence Albiges, Ronan Flippot, Bernard Escudier
Cardiovascular and Interventional Radiology|June 10, 2010
Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasisPramod Rao, Bernard Escudier, Thierry de Baere
Bulletin Du Cancer|March 31, 2015
[Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines]Bernard Escudier, Florence Joly, Jean-Charles Soria
European Urology|November 12, 2017
Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8Robert J Motzer, Bernard Escudier, Alain Ravaud
Targeted Oncology|June 22, 2010
Targeting mTOR in cancer: renal cell is just a beginningHamdy Azim, Hatem A Azim, Bernard Escudier
Cancer Treatment Reviews|July 31, 2009
Trastuzumab versus lapatinib: the cardiac side of the storyHamdy Azim, Hatem A Azim, Bernard Escudier
Journal of Nephrology|September 21, 2013
Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?Hassane Izzedine, Jean Charles Soria, Bernard Escudier
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 12, 2008
Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma ForumLori A Wood, Bernard Escudier, Neil Reaume
Expert Opinion on Pharmacotherapy|November 12, 2016
Cabozantinib for the treatment of renal cell carcinomaBernard Escudier, Julie C Lougheed, Laurence Albiges
Pageof 37

Showing results (41-50 of 362) with videos related to

Sort By:
Pageof 37
Future Oncology (London, England)|October 18, 2014
Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trialAmikumar Mehta, Guru Sonpavde, Bernard Escudier
European Urology|March 28, 2021
Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?Laurence Albiges, Ronan Flippot, Bernard Escudier
Cardiovascular and Interventional Radiology|June 10, 2010
Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasisPramod Rao, Bernard Escudier, Thierry de Baere
Bulletin Du Cancer|March 31, 2015
[Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines]Bernard Escudier, Florence Joly, Jean-Charles Soria
European Urology|November 12, 2017
Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8Robert J Motzer, Bernard Escudier, Alain Ravaud
Targeted Oncology|June 22, 2010
Targeting mTOR in cancer: renal cell is just a beginningHamdy Azim, Hatem A Azim, Bernard Escudier
Cancer Treatment Reviews|July 31, 2009
Trastuzumab versus lapatinib: the cardiac side of the storyHamdy Azim, Hatem A Azim, Bernard Escudier
Journal of Nephrology|September 21, 2013
Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?Hassane Izzedine, Jean Charles Soria, Bernard Escudier
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 12, 2008
Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma ForumLori A Wood, Bernard Escudier, Neil Reaume
Expert Opinion on Pharmacotherapy|November 12, 2016
Cabozantinib for the treatment of renal cell carcinomaBernard Escudier, Julie C Lougheed, Laurence Albiges
Pageof 37